CD38 – Lymphocyte Marker and a Future Immunotherapeutic Target
CD38 is a type II transmembrane glycoprotein of 45 kDa with a protein core of 35 kDa. The CD38 antigen is expressed on essentially all pre-B lymphocytes, plasma cells, and thymocytes. It is also present on activated T lymphocytes, natural killer (NK) lymphocytes, myeloblasts, and erythroblasts. The antigen is expressed during the early stages of T- and B-lymphocyte differentiation, is lost during the intermediate stages of maturation, and then reappears during the final stages of maturation. The CD38 antigen is expressed on 90% of CD34+ cells, and is not expressed on pluripotent stem cells. Coexpression of CD38 antigen on CD34+ cells indicates lineage commitment of those cells. CD38 is a counter-receptor of CD31. It is also expressed in T- and B-acute lymphoblastic leukemia (ALL), Burkitts lymphoma, multiple myeloma, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL).
CD38 is a significant molecule of the moment, and the citations of this molecule are more than 2000 articles in the past 5 years. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines (J Leukoc Biol. 2005;77(4):513-21). CD38 is also highly expressed in long-lived bone marrow-derived plasma cell, defined as CD19−CD38hiCD138+ population (Nat Commun. 2017; 8(1):1781).
The OKT10 directed against human CD38 antigen. CBI provides multiple fluorophore conjugations to meet your research/clinical trials needs: